BRAF and neoplasm: In clinical practice, the prominence of this effect is mainly ascribable to melanoma treatment; in fact, in about 40–60% of patients affected by cutaneous melanoma, tumor cells harbor a specific mutation called BRAF-V600E, which results as targetable by BRAF inhibitors which interfere with this signal transduction pathway, causing apoptosis in melanoma cells [3,8,9].